Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPRX |
---|---|---|
09:32 ET | 41130 | 27.14 |
09:34 ET | 2900 | 27.17 |
09:36 ET | 2700 | 27.24 |
09:38 ET | 106 | 27.25 |
09:39 ET | 6220 | 27.35 |
09:41 ET | 7721 | 27.47 |
09:43 ET | 14676 | 27.49 |
09:45 ET | 4732 | 27.38 |
09:48 ET | 3700 | 27.39 |
09:50 ET | 5317 | 27.395 |
09:52 ET | 5000 | 27.44 |
09:54 ET | 5100 | 27.36 |
09:56 ET | 3089 | 27.375 |
09:57 ET | 11500 | 27.43 |
09:59 ET | 9971 | 27.49 |
10:01 ET | 5159 | 27.48 |
10:03 ET | 10307 | 27.56 |
10:06 ET | 9393 | 27.575 |
10:08 ET | 5323 | 27.54 |
10:10 ET | 3372 | 27.555 |
10:12 ET | 4319 | 27.56 |
10:14 ET | 5456 | 27.62 |
10:15 ET | 8124 | 27.645 |
10:17 ET | 10430 | 27.59 |
10:19 ET | 6271 | 27.615 |
10:21 ET | 6661 | 27.59 |
10:24 ET | 8094 | 27.63 |
10:26 ET | 6110 | 27.615 |
10:28 ET | 11231 | 27.635 |
10:30 ET | 29481 | 27.6 |
10:32 ET | 3780 | 27.585 |
10:33 ET | 5969 | 27.56 |
10:35 ET | 500 | 27.555 |
10:37 ET | 5315 | 27.5599 |
10:39 ET | 5110 | 27.595 |
10:42 ET | 4453 | 27.6199 |
10:44 ET | 8101 | 27.605 |
10:46 ET | 600 | 27.605 |
10:48 ET | 4888 | 27.6112 |
10:50 ET | 11155 | 27.635 |
10:51 ET | 2901 | 27.615 |
10:53 ET | 3880 | 27.605 |
10:55 ET | 9639 | 27.6 |
10:57 ET | 6488 | 27.6 |
11:00 ET | 7168 | 27.565 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Royalty Pharma PLC | 16.4B | 15.5x | +1.83% |
Amneal Pharmaceuticals Inc | 2.1B | -11.9x | --- |
Catalent Inc | 9.7B | -8.7x | --- |
Jazz Pharmaceuticals PLC | 6.6B | 22.8x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Prestige Consumer Healthcare Inc | 3.2B | 15.7x | --- |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.4B |
---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 597.4M |
Dividend Yield | 3.05% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 05-16-24 |
Pay Date | 06-14-24 |
Beta | 0.47 |
EPS | $1.78 |
Book Value | $14.61 |
P/E Ratio | 15.5x |
Price/Sales (TTM) | 7.3 |
Price/Cash Flow (TTM) | 13.7x |
Operating Margin | 41.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.